Product news

Share this article:

Roche said the FDA has approved a supplemental New Drug Application to market Tamiflu (oseltamivir phosphate) capsules in 30 mg and 45 mg doses. The lower dose capsules provide an alternative for the treatment and prevention of influenza types A and B in patients one year and older. Since the capsules have a longer shelf life than the liquid suspension formulation (five years vs. 24 months), they also offer an improved option for government pandemic stockpiling. Tamiflu will continue to be available in a 75 mg capsule for adults as well as liquid suspension formulation for children. The 30 mg and 45 mg capsules will be available in pharmacies nationwide and for government stockpiling for the 2007-2008 flu season. To date, Roche has filled orders from the US federal government and states for 43.7 million Tamiflu treatment courses.

Bradley Pharmaceuticals announced that its Doak Dermatologics subsidiary recently launched two new product line extensions from its Kerol and Rosula brand portfolios. Kerol topical suspension (50% Urea), a potent keratolytic in a vehicle containing lactic acid & salicylic acid, is an addition to the line of Kerol Redi-Cloths keratolytic moisturizers. Kerol topical suspension is indicated for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses. Rosula clarifying wash (sodium sulfacetamide 10% and sulfur 4%) is the fourth product launched under the Rosula brand. The new Rosula clarifying wash formulation combines 10% sodium sulfacetamide and 4% sulfur in a urea vehicle and is indicated for the treatment of acne vulgaris, acne rosacea and seborrrheic dermatitis. Bradley launched the Rosula brand in 2003 with Rosula Aqueous Gel which was followed by Rosula aqueous cleanser and Rosula NS medicated pads.

Fosteum (capsules), designed to safely address the underlying disease processes of osteopenia and osteoporosis, is now available nationwide from Primus Pharmaceuticals.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.